A natural variant of the heme-binding signature (R441C) resulting in complete loss of function of CYP2D6

Drug Metabolism and Disposition

Volumn 35, Issue 8, 2007, Pages 1247-1250

  Klein, Kathrin ^a,b   Tatzel, Stephan ^c   Raimundo, Sebastian ^a,b   Saussele, Tanja ^a,b   Hustert, Elisabeth ^d   Pleiss, Jürgen ^c   Eichelbaum, Michel ^a,b   Zanger, Ulrich M ^a,b  

^a DR MARGARETE FISCHER BOSCH INSTITUTE OF CLINICAL PHARMACOLOGY   (Germany)

^b UNIVERSITY OF TÜBINGEN   (Germany)

^c UNIVERSITY OF STUTTGART   (Germany)

^d Epidauros Biotechnologie AG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID; CYTOCHROME P450 2D6; HEME; PROPAFENONE; SPARTEINE; UNSPECIFIC MONOOXYGENASE;

ALLELE; ARTICLE; GENE FUNCTION; GENETIC VARIABILITY; MAMMAL; NUCLEOTIDE SEQUENCE; PHENOTYPE; PRIORITY JOURNAL;

AMINO ACID SEQUENCE; ARGININE; BINDING SITES; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CONSENSUS SEQUENCE; CYTOCHROME P-450 CYP2D6; CYTOCHROME P-450 ENZYME SYSTEM; GENE FREQUENCY; GENOTYPE; HEME; HETEROZYGOTE; HUMANS; MODELS, MOLECULAR; POLYMORPHISM, SINGLE NUCLEOTIDE; PROPAFENONE; PROTEIN BINDING; RECOMBINANT PROTEINS; SEQUENCE HOMOLOGY, AMINO ACID; SPARTEINE;

MAMMALIA;

EID: 34547209907     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.107.015149     Document Type: Article

References (20)

1. Allorge D, Breant D, Harlow J, Chowdry J, Lo-Guidice JM, Chevalier D, Cauffiez C, Lhermitte M, Blaney FE, Tucker GT, et al. (2005) Functional analysis of CYP2D6.31 variant: homology modeling suggests possible disruption of redox partner interaction by Arg440His substitution. Proteins 59:339-346.
2. Benson DA, Karsch-Mizrachi I, Lipman DJ, Ostell J, and Wheeler DL (2006) GenBank. Nucleic Acids Res 34:D16-D20.
3. Curnow KM, Slutsker L, Vitek J, Cole T, Speiser PW, New MI, White PC, and Pascoe L (1993) Mutations in the CYP11B1 gene causing congenital adrenal hyperplasia and hypertension cluster in exons 6, 7, and 8. Proc Natl Acad Sci U S A 90:4552-4556.
4. Evert B, Eichelbaum M, Haubruck H, and Zanger UM (1997) Functional properties of CYP2D6 1 (wild-type) and CYP2D6 7 (His324Pro) expressed by recombinant baculovirus in insect cells. Naunyn Schmiedebergs Arch Pharmacol 355:309-318.
5. Griese EU, Zanger UM, Brudermanns U, Gaedigk A, Mikus G, Morike K, Stuven T, and Eichelbaum M (1998) Assessment of the predictive power of genotypes for the in-vivo catalytic function of CYP2D6 in a German population. Pharmacogenetics 8:15-26.
6. Ibeanu GC, Blaisdell J, Ghanayem BI, Beyeler C, Benhamou S, Bouchardy C, Wilkinson GR, Dayer P, Daly AK, and Goldstein JA (1998) An additional defective allele, CYP2C19*5, contributes to the S-mephenytoin poor metabolizer phenotype in Caucasians. Pharmacogenetics 8:129-135.
7. Ito Y, Fisher CR, Conte FA, Grumbach MM, and Simpson ER (1993) Molecular basis of aromatase deficiency in an adult female with sexual infantilism and polycystic ovaries. Proc Natl Acad Sci U S A 90:11673-11677.
8. Klein K, Lang T, Saussele T, Barbosa-Sicard E, Schunck WH, Eichelbaum M, Schwab M, and Zanger UM (2005) Genetic variability of CYP2B6 in populations of African and Asian origin: allele frequencies, novel functional variants, and possible implications for anti-HIV therapy with efavirenz. Pharmacogenet Genomics 15:861-873.
9. Li H and Poulos TL (2004) Crystallization of cytochromes P450 and substrate-enzyme interactions. Curr Top Med Chem 4:1789-1802.
10. Nelson DR, Koymans L, Kamataki T, Stegeman JJ, Feyereisen R, Waxman DJ, Waterman MR, Gotoh O, Coon MJ, Estabrook RW, et al. (1996) P450 superfamily: update on new sequences, gene mapping, accession numbers and nomenclature. Pharmacogenetics 6:1-42.
11. Pei J and Grishin NV (2001) AL2CO: calculation of positional conservation in a protein sequence alignment. Bioinformatics 17:700-712.
12. Raimundo S, Toscano C, Klein K, Fischer J, Griese EU, Eichelbaum M, Schwab M, and Zanger UM (2004) A novel intronic mutation, 2988G>A, with high predictivity for impaired function of cytochrome P450 2D6 in white subjects. Clin Pharmacol Ther 76:128-138.
13. Rowland P, Blaney FE, Smyth MG, Jones JJ, Leydon VR, Oxbrow AK, Lewis CJ, Tennant MG, Modi S, Eggleston DS, et al. (2006) Crystal structure of human cytochrome P450 2D6. J Biol Chem 281:7614-7622.
14. Saito Y, Hanioka N, Maekawa K, Isobe T, Tsuneto Y, Nakamura R, Soyama A, Ozawa S, Tanaka-Kagawa T, Jinno H, et al. (2005) Functional analysis of three CYP1A2 variants found in a Japanese population. Drug Metab Dispos 33:1905-1910.
15. Schaeffeler E, Fischer C, Brockmeier D, Wernet D, Moerike K, Eichelbaum M, Zanger UM, and Schwab M (2004) Comprehensive analysis of thiopurine S-methyltransferase phenotype-genotype correlation in a large population of German-Caucasians and identification of novel TPMT variants. Pharmacogenetics 14:407-417.
16. Shimizu T, Tateishi T, Hatano M, and Fujii-Kuriyama Y (1991) Probing the role of lysines and arginines in the catalytic function of cytochrome P450d by site-directed mutagenesis. Interaction with NADPH-cytochrome P450 reductase. J Biol Chem 266:3372-3375.
17. Thompson JD, Gibson TJ, Plewniak F, Jeanmougin F, and Higgins DG (1997) The CLUSTAL_X windows interface: flexible strategies for multiple sequence alignment aided by quality analysis tools. Nucleic Acids Res 25:4876-4882.
18. Toscano C, Raimundo S, Klein K, Eichelbaum M, Schwab M, and Zanger UM (2006) A silent mutation (2939G>A, exon 6; CYP2D6*59) leading to impaired expression and function of CYP2D6. Pharmacogenet Genomics 16:767-770.
19. Wolbold R, Klein K, Burk O, Nussler AK, Neuhaus P, Eichelbaum M, Schwab M, and Zanger UM (2003) Sex is a major determinant of CYP3A4 expression in human liver. Hepatology 38:978-988.
20. Zanger UM, Raimundo S, and Eichelbaum M (2004) Cytochrome P450 2D6: overview and update on pharmacology, genetics, biochemistry. Naunyn Schmiedebergs Arch Pharmacol 369:23-37.